Pyridoxine administration in sickle cell disease: an unsuccessful attempt to influence the properties of sickle hemoglobin.
D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D001219:Aspartate Aminotransferases / Q000097:blood; D001809:Blood Viscosity / Q000187:drug effects; D002859:Chromium Isotopes; D004912:Erythrocytes / Q000201:enzymology; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism; D006455:Hemoglobins, Abnormal / Q000378:metabolism*; D006801:Humans; D010100:Oxygen / Q000097:blood; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D011736:Pyridoxine / Q000627:therapeutic use*; D012545:Schiff Bases; D013789:Thalassemia / Q000097:blood / Q000188:drug therapy
D002859:Chromium Isotopes; D006454:Hemoglobins; D006455:Hemoglobins, Abnormal; D012545:Schiff Bases; D011732:Pyridoxal Phosphate; D001219:Aspartate Aminotransferases; D011736:Pyridoxine; D010100:Oxygen